EU watchdog asks if drug makers influence EMA decisions
December 05, 2017 Drug companies meet with the EMA to discuss their drugs and development programs throughout the R&D process. The EMA sees such meetings as facilitating the speedy development of safe and effective medicines, leading it to make early, frequent engagement a cornerstone of its initiatives to cut the time it takes to get … Read more